Src inhibitors in lung cancer: Current status and future directions

Clinical Lung Cancer

Volumn 11, Issue 4, 2010, Pages 238-242

  Rothschild, Sacha ^a   Gautschi, Oliver ^a   Haura, Eric ^b   Johnson, Faye ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Bosutinib; Dasatinib; EGFR; Saracatinib

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; BOSUTINIB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; DASATINIB; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; KX 2 391; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; OXALIPLATIN; PACLITAXEL; SRC INHIBITOR; UNCLASSIFIED DRUG; XL 228; XL 999; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HUMAN; KIDNEY FAILURE; LEUKEMIA; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; PROSTATE CANCER; REVIEW; SEPTIC SHOCK; SOLID TUMOR; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); ENZYMOLOGY; LUNG NEOPLASMS; PATHOLOGY;

CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES;

EID: 77957113984     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.030     Document Type: Review

References (56)

1. Rous P. A transmissible avian neoplasm. (Sarcoma of the common fowl) by Peyton Rous, M.D., Experimental Medicine for Sept. 1, 1910, vol.12, pp.696-705. J Exp Med 1979; 150:729-53.
2. Hecker TP, Grammer JR, Gillespie GY, et al. Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res 2002; 62:2699-2707
3. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13:513-609.
4. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006; 12:1398-1401
5. Kiefer PE, Bepler G, Kubasch M, et al. Amplification and expression of proto-oncogenes in human small-cell lung cancer cell lines. Cancer Res 1987; 47:6236-6242
6. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22:337-358
7. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000; 19:5636-5642
8. Mao W, Irby R, Coppola D, et al. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 1997; 15:3083-3090 (Pubitemid 28043487)
9. Sos ML, Michel K, Zander T, et al. Predicting drug susceptibility of non-small-cell lung cancers based on genetic lesions. J Clin Invest 2009; 119:1727-1740
10. Brown MT, Cooper JA. Regulation, substrates and functions of sRC. Biochim Biophys Acta 1996; 1287:121-149
11. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4:470-480
12. Shah AN, Gallick GE. Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs 2007; 18:371-375
13. Gautschi O, Tepper CG, Purnell PR, et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res 2008; 68:2250-2258
14. de Vries TJ, Mullender MG, van Duin MA, et al. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res 2009; 7:476-488
15. Mellstrom K, Bjelfman C, Hammerling U, et al. Expression of c-sRC in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation. Mol Cell Biol 1987; 7:4178-4184
16. Mazurenko NN, Kogan EA, Zborovskaya IB, et al. Expression of pp60c-src in human small- cell and non-small-cell lung carcinomas. Eur J Cancer 1992; 28:372-377
17. Budde RJ, Ke S, Levin VA. Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys 1994; 14:171-175
18. Masaki T, Igarashi K, Tokuda M, et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer 2003; 39:1447-1455
19. Rothschild S, Kappeler A, Ratschiller D, et al. The putative cancer stem cell gene Inhibitor of differentiation 1 (ID1) is frequently expressed in primary non-small cell lung cancer. Paper presented at: the 13th World Conference on Lung Cancer; July 31-August 4, 2009; San Francisco, CA. Abstract P1.032.
20. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6:587-595
21. Song L, Turkson J, Karras JG, et al. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003; 22:4150-4165
22. Johnson FM, Saigal B, Talpaz M, et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11:6924-6932
23. Song L, Morris M, Bagui T, et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006; 66:5542-5548
24. Purnell PR, Mack PC, Tepper CG, et al. The Src Inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol 2009.
25. Lee D, Gautschi O. Clinical development of SRC tyrosine kinase inhibitors in lung cancer. Clin Lung Cancer 2006; 7:381-384
26. Evans RR, Morgan JA, van den Abbeele AD. Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumours. J Clin Oncol 2005; 23(16 suppl):200s (Abstract 3034).
27. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15:7421-7428
28. Johnson FM, Tang X, Tran B, et al. Phase II study of dasatinib in non-small-cell lung cancer (NSCLC). Paper presented at: the 2009 Annual Meeting of the American Society of Clinical Oncology; May 29-June 2, 2009; Orlando, FL. Abstract e19015.
29. Araujo J, Armstrong AJ, Braud EL, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol 2009; 27(15 suppl):249s (abstract 5061).
30. Chiappori AA, Tanvetyanon T, Williams CA, et al. Phase I trial evaluating the epidermal growth factor receptor inhibitor erlotinib in combination with the SRC kinase inhibitor dasatinib for patients with recurrent non-small-cell lung cancer (NSCLC). J Clin Oncol 2008; 26(15 suppl):635s (abstract 14605).
31. Feinstein TM, Agrawal S, Stoller RG, et al. A. Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies. J Clin Oncol 2009; 27(15 suppl):156s (abstract 3540).
32. Vemulapalli S, Kurzrock R, Fritsche H, et al. Phase I open-labeled trial of gemcitabine and dasatinib in advanced solid tumors. J Clin Oncol 2008; 26(15 suppl):637s (abstract 14626).
33. Haura EB, Tanvetyanon T, Chiappori A, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28(8):1387-1394
34. Lockton JA, Smethurst D, Macpherson M, et al. Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor. J Clin Oncol 2005; 23(16 suppl):223s (abstract 3125).
35. Eastell R, Hannon RA, Gallagher N, et al. The effect of AZD0530, a highly selective, orally available Src/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males. J Clin Oncol 2005; 23(16 suppl):202s (abstract 3041).
36. Tabernero J, Cervantes A, Hoekman K, et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. J Clin Oncol 2007; 25(18 suppl):143s (abstract 3520).
37. Eng C, Kopetz S, Morris M, et al. Phase II study of the novel oral Src-kinase inhibitor, AZD0530, in previously treated advanced colorectal cancer patients. AACR Meeting Abstracts 2008; LB-76.
38. Trarbach T, Drevs J, Strumberg D, et al. A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors. J Clin Oncol 2008; 26(15 suppl):175s (abstract 3592).
39. Messersmith WA, Krishnamurthi S, Hewes BA, et al. Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J Clin Oncol 2007; 25(18 suppl):150s (abstract 3552).
40. Cooper JA, Mita MM, Curtright J, et al. A phase I study examining weekly dosing and pharmacokinetics (PK) of a novel spectrum selective kinase inhibitor, XL999, in patients (pts) with advanced solid malignancies (ASM). J Clin Oncol 2006; 24(18 suppl):603s (abstract 13024).
41. March RJ, Mirtsching B, Modi S, et al. A phase II study of XL999 in patients (pts) with NSCLC. J Clin Oncol 2007; 25(18 suppl):692s (abstract 18112).
42. Cripe L, McGuire W, Wertheim M, et al. Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM). J Clin Oncol 2007; 25(18 suppl):160s (abstract 3591).
43. Smith DC, Britten C, Clary DO, et al. A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies. J Clin Oncol 2009; 27(15 suppl):149s (abstract 3512).
44. Zheng R, Yano S, Matsumori Y, et al. SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells. Clin Exp Metastasis 2005; 22:195-204.
45. Bu Y, Gao L, Smolinski M, et al. KXO1 (KX2-391), a Src-family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation in vitro and in vivo. Paper presented at: the 99th AACR Annual Meeting; April 12-16, 2008; San Diego, CA. Abstract 4983.
46. Adjei AA, Cohen RB, Kurzrock R, et al. Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. J Clin Oncol 2009; 27(15 suppl):148s (abstract 3511).
47. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004; 23:7957-7968
48. Zhang J, Kalyankrishna S, Wislez M, et al. SRC-family kinases are activated in non-small-cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007; 170:366-376
49. Chung BM, Dimri M, George M, et al. The role of cooperativity with Src in oncogenic transformation mediated by non-small-cell lung cancer-associated EGF receptor mutants. Oncogene 2009; 28:1821-1832
50. Haura EB. SRC and STAT pathways. J Thorac Oncol 2006; 1:403-405
51. Byers LA, Sen B, Saigal B, et al. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res; 2009; 15:6852-6861
52. Sen B, Saigal B, Parikh N, et al. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 2009; 69:1958-1965.
53. Kopetz S, Lesslie DP, Dallas NA, et al. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009; 69:3842-3849
54. Ceppi P, Papotti M, Monica V, et al. Effects of Src kinase inhibition induced by dasatinib in non-small-cell lung cancer cell lines treated with cisplatin. Mol Cancer Ther 2009; 8:3066-3074
55. Duxbury MS, Ito H, Zinner MJ, et al. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004; 10:2307-2318
56. Boudny V, Nakano S. Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells. Anticancer Res 2003; 23;7-12.